Atlas Venture is systematically unwinding a large position built since 2020. The proposed 76,650 shares is a small continuation of a much larger weekly pace ($15-57M/day June 22-26). Monitor for additional 144s if Atlas intends to dispose of its remaining stake. The ongoing selling is a technical overhang but not a negative signal on Kymera's business fundamentals given the 93% analyst buy consensus and strong institutional ownership.
Price Chart
Executive Summary
Atlas Venture, a founding VC investor in Kymera Therapeutics, has filed two Form 144 notices to sell a combined 76,650 shares of common stock valued at approximately $8.3M (~0.09% of market cap). These filings follow a remarkable 9 consecutive days of heavy Atlas Venture selling (April through late June 2026) totaling over 1.6 million shares worth ~$157M, as disclosed in the same filing's recent transaction history. The selling is part of a systematic, pre-planned secondary distribution by a venture fund that owned the shares since a 2020 private placement and is well past its standard lock-up. While the 76,650 share amount is small relative to the prior week's pace (>1.4M shares sold June 17-26), the filings confirm Atlas continues to monetize its position in an orderly manner. This does not reflect management's view of the business — Kymera has 93% analyst buy ratings and a $9.4B market cap — but the persistent supply overhang is a real technical factor.
Key Facts
- Atlas Venture Fund X, L.P. filed Form 144 to sell 66,177 shares at ~$7.16M.
- Atlas Venture Opportunity Fund I, L.P. filed Form 144 to sell 10,473 shares at ~$1.13M.
- Combined proposed sale: 76,650 shares worth ~$8.29M (0.09% of $9.4B market cap).
- Filings disclose Atlas Venture funds sold over 1.6 million shares between June 17-26, 2026 totaling ~$157M.
- Shares were originally acquired in a private placement on March 11, 2020 — well beyond any lock-up.
- The seller is Atlas Venture, a founding venture capital investor, not company management.
Financial Impact
Proposed sale of ~$8.3M, part of a much larger $157M selling program over 9 trading days in June 2026
Risk Factors
- Continued Atlas Venture selling could pressure the stock in the near term regardless of fundamentals
- Liquidity risk: if Atlas accelerates selling, the stock may struggle to absorb the supply
- No cross-filing context to suggest any negative catalyst — this is pure VC distribution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (KYMR) — Batch item 1 | 0001628280-26-046098 |
| Document: 0001628280-26-046098-index.html | 0001628280-26-046097 |
| Document: 0001628280-26-046098.txt | 0001628280-26-046098 |
| 144 Filing (KYMR) — Batch item 4 | 0001628280-26-046097 |
| Document: 0001628280-26-046097-index.html | 0001628280-26-046098 |
| Document: 0001628280-26-046097.txt | 0001628280-26-046098 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $105.48 $118.63 | ▲ +12.47% | ▲ +13.07% | $107.39 (+1.81%) |
Jul 8, 2026 12w ago | Insider Cluster | $114.16 $105.48 | ▲ +7.60% | ▲ +10.88% | $107.39 (+5.93%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jun 30, 2026 13w ago | 144 | $114.20 $105.25 | ▲ +7.84% | ▲ +5.65% | $107.39 (+5.96%) |
Jun 29, 2026 13w ago | 144 | $114.67 $110.05 | ▼ −4.03% | ▼ −3.00% | $107.39 (−6.35%) |
Jun 26, 2026 13w ago | Insider Cluster | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 13w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 13w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 24, 2026 14w ago | 144 | $116.46 $110.38 | ▼ −5.22% | ▼ −5.75% | $107.39 (−7.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access